Detalhe da pesquisa
1.
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Cancer
; 123(16): 3141-3149, 2017 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472539
2.
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Br J Haematol
; 169(1): 36-43, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25572917
3.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J
; 13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726298